Added to YB: 2026-07-29
Pitch date: 2026-07-24
GSK.L [neutral]
GSK plc
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 76.4B
Pitch Price
N/A
Price Target
N/A
Dividend
3.75%
EV/EBITDA
7.88
P/E
13.52
EV/Sales
2.80
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 24/7/2026 - GSK – Pipeline progress
GSK.L (update): Pipeline progress — EMA accepted Bexsero label update for Meningitis B booster in 10+ yr olds (registered in 61 countries); Jideytro won US approval for NSCLC, GSK's first lung cancer approval. 57 potential new vaccines/medicines in pipeline. Cheap at 9.8x 2027 earnings, 3.8% yield.
Read full article (1 min)